Multiple myeloma care is evolving faster than ever, with new therapies, treatment strategies, and possibilities emerging at an unprecedented pace. In this episode, hematologist Dr. Devarakonda and Kathy Giusti, founder of the Multiple Myeloma Research Foundation, come together for a candid, practical conversation about what this rapid progress means for patients, caregivers, and providers.They explore why where you’re treated matters, how timing, sequencing, and dosing decisions shape outcomes, and what it takes to be an informed patient in today’s complex care environment. Through real-world stories and clinical insight, the conversation highlights the importance of collaboration between community and academic care teams, the growing role of the patient voice in decision-making, and the need to balance cutting-edge treatment with quality of life.Whether newly diagnosed or navigating later lines of therapy, this episode offers practical guidance for making confident, informed decisions in multiple myeloma care.Key TakeawaysMultiple myeloma is increasingly treatable, with patients living longer than everAdvances in therapy are leading to remission for many patients and significantly improving survival outcomes.Where you’re treated—and your care team—matters more than everThe most effective care is team-based, involving academic specialists, community oncologists, and the patient along with their caregiver working together.Treatment decisions are more complex: timing, sequencing, and dosing all matterWith a growing number of options, patients and providers must navigate when and how to use therapies through ongoing, informed discussions.Being informed is essential to navigating care todayPatients have more access to information than ever before, and using that information effectively supports shared decision-making with their care team.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related